Full Text
PMH26 USING THE NET-BENEFIT REGRESSION APPROACH TO COMPARE THE COST-EFFECTIVENESS OF HALOPERIDOL, OLANZAPINE AND RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA

Abstract

Authors

A De Ridder D De Graeve

Back to Volume 10, Issue 6
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×